An Open-label, Phase I, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of NT 112 in Human Leukocyte Antigen-C08:02 Positive Adult Subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation.

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT06218914

Study #:
STUDY00160329

Start Date:
Oct 15, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06218914

View Complete Trial Details & Eligibility at ClinicalTrials.gov